Skip to main content
Top
Published in: Breast Cancer Research 3/2002

01-06-2002 | Commentary

Hormonal control of p53 and chemoprevention

Authors: D Joseph Jerry, Lisa M Minter, Klaus A Becker, Anneke C Blackburn

Published in: Breast Cancer Research | Issue 3/2002

Login to get access

Abstract

Improvements in the detection and treatment of breast cancer have dramatically altered its clinical course and outcome. However, prevention of breast cancer remains an elusive goal. Parity, age of menarche, and age at menopause are major risk factors drawing attention to the important role of the endocrine system in determining the risk of breast cancer, while heritable breast cancer susceptibility syndromes have implicated tumor suppressor genes as important targets. Recent work demonstrating hormonal modulation of the p53 tumor suppressor pathway draws together these established determinants of risk to provide a model of developmental susceptibility to breast cancer. In this model, the mammary epithelium is rendered susceptible due to impaired p53 activity during specific periods of mammary gland development, but specific endocrine stimuli serve to activate p53 function and to mitigate this risk. The results focus attention on p53 as a molecular target for therapies to reduce the risk of breast cancer.
Literature
1.
go back to reference Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994, 139: 819-835.PubMed Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994, 139: 819-835.PubMed
2.
go back to reference Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997, 79: 1203-1210. 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2.CrossRefPubMed Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997, 79: 1203-1210. 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2.CrossRefPubMed
3.
go back to reference Land CE: Radiation and breast cancer risk. Prog Clin Biol Res. 1997, 396: 115-124.PubMed Land CE: Radiation and breast cancer risk. Prog Clin Biol Res. 1997, 396: 115-124.PubMed
4.
go back to reference Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Biology of disease: comparative study of human and rat tumorigenesis. Lab Invest. 1990, 62: 244-278.PubMed Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Biology of disease: comparative study of human and rat tumorigenesis. Lab Invest. 1990, 62: 244-278.PubMed
5.
go back to reference Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ: Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res. 2000, 60: 2723-2729.PubMed Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ: Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res. 2000, 60: 2723-2729.PubMed
6.
go back to reference Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW, Medina D: Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis. 1998, 19: 1573-1581. 10.1093/carcin/19.9.1573.CrossRefPubMed Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW, Medina D: Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis. 1998, 19: 1573-1581. 10.1093/carcin/19.9.1573.CrossRefPubMed
7.
go back to reference Sivaraman L, Conneely OM, Medina D, O'Malley BW: p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA. 2001, 98: 12379-12384. 10.1073/pnas.221459098.CrossRefPubMedPubMedCentral Sivaraman L, Conneely OM, Medina D, O'Malley BW: p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA. 2001, 98: 12379-12384. 10.1073/pnas.221459098.CrossRefPubMedPubMedCentral
8.
go back to reference Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson ES, Marconi S, Naber SP: Delayed involution of the mammary epithelium in BALB/c-p53 null mice. Oncogene. 1998, 17: 2305-2312. 10.1038/sj/onc/1202157.CrossRefPubMed Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson ES, Marconi S, Naber SP: Delayed involution of the mammary epithelium in BALB/c-p53 null mice. Oncogene. 1998, 17: 2305-2312. 10.1038/sj/onc/1202157.CrossRefPubMed
9.
go back to reference Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA. 1999, 96: 2520-2525. 10.1073/pnas.96.5.2520.CrossRefPubMedPubMedCentral Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA. 1999, 96: 2520-2525. 10.1073/pnas.96.5.2520.CrossRefPubMedPubMedCentral
10.
go back to reference Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001/jama.281.23.2189.CrossRefPubMed Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001/jama.281.23.2189.CrossRefPubMed
11.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed
12.
go back to reference Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW: Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59: 4276-4284.PubMed Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW: Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59: 4276-4284.PubMed
13.
go back to reference Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000, 283: 485-491. 10.1001/jama.283.4.485.CrossRefPubMed Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000, 283: 485-491. 10.1001/jama.283.4.485.CrossRefPubMed
14.
go back to reference Christov K, Swanson SM, Guzman RC, Thordarson G, Jin E, Talamantes F, Nandi S: Kinetics of mammary epithelial cell proliferation in pituitary isografted BALB/c mice. Carcinogenesis. 1993, 14: 2019-2025.CrossRefPubMed Christov K, Swanson SM, Guzman RC, Thordarson G, Jin E, Talamantes F, Nandi S: Kinetics of mammary epithelial cell proliferation in pituitary isografted BALB/c mice. Carcinogenesis. 1993, 14: 2019-2025.CrossRefPubMed
15.
go back to reference Medina D: The mammary gland: a unique organ for the study of development and tumorigenesis. Mammary Gland Biol Neoplasia. 1996, 1: 5-19.CrossRef Medina D: The mammary gland: a unique organ for the study of development and tumorigenesis. Mammary Gland Biol Neoplasia. 1996, 1: 5-19.CrossRef
16.
go back to reference Irwin KL, Lee NC, Peterson HB, Rubin GI, Wingo PA, Mandel MG, the Cancer and Steroid Hormone Study Group: Hysterectomy, tubal sterilization, and the risk of breast cancer. Am J Epidemiol. 1988, 127: 1192-1201.PubMed Irwin KL, Lee NC, Peterson HB, Rubin GI, Wingo PA, Mandel MG, the Cancer and Steroid Hormone Study Group: Hysterectomy, tubal sterilization, and the risk of breast cancer. Am J Epidemiol. 1988, 127: 1192-1201.PubMed
17.
go back to reference Thordarson G, Van Horn K, Guzman RC, Nandi S, Talamantes F: Parous rats regain high susceptibility to chemically induced mammary cancer after treatment with various mammotropic hormones. Carcinogenesis. 2001, 22: 1027-1033. 10.1093/carcin/22.7.1027.CrossRefPubMed Thordarson G, Van Horn K, Guzman RC, Nandi S, Talamantes F: Parous rats regain high susceptibility to chemically induced mammary cancer after treatment with various mammotropic hormones. Carcinogenesis. 2001, 22: 1027-1033. 10.1093/carcin/22.7.1027.CrossRefPubMed
18.
go back to reference Bolander FF: Persistent alterations in hormonal sensitivities of mammary glands from parous mice. Endocrinology. 1983, 112: 1796-1800.CrossRefPubMed Bolander FF: Persistent alterations in hormonal sensitivities of mammary glands from parous mice. Endocrinology. 1983, 112: 1796-1800.CrossRefPubMed
19.
go back to reference Bolander FF: Loss of differentiative potential of the mammary gland in ovariectomized mice: altered estrogen responsiveness in parous mice. Dev Biol. 1983, 98: 510-514.CrossRefPubMed Bolander FF: Loss of differentiative potential of the mammary gland in ovariectomized mice: altered estrogen responsiveness in parous mice. Dev Biol. 1983, 98: 510-514.CrossRefPubMed
21.
go back to reference Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 1998, 17: 1681-1689. 10.1038/sj/onc/1202106.CrossRefPubMed Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 1998, 17: 1681-1689. 10.1038/sj/onc/1202106.CrossRefPubMed
22.
go back to reference Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD: TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 2001, 61: 4092-4097.PubMed Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD: TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 2001, 61: 4092-4097.PubMed
23.
go back to reference Rebbeck TR: Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000, 18: 100S-103S.PubMed Rebbeck TR: Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000, 18: 100S-103S.PubMed
24.
go back to reference Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000, 343: 78-85. 10.1056/NEJM200007133430201.CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000, 343: 78-85. 10.1056/NEJM200007133430201.CrossRefPubMed
25.
go back to reference Yu Y, Okayasu R, Weil MM, Silver A, McCarthy M, Zabriskie R, Long S, Cox R, Ullrich RL: Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 2001, 61: 1820-1824.PubMed Yu Y, Okayasu R, Weil MM, Silver A, McCarthy M, Zabriskie R, Long S, Cox R, Ullrich RL: Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 2001, 61: 1820-1824.PubMed
26.
go back to reference Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science. 1999, 286: 2507-2510. 10.1126/science.286.5449.2507.CrossRefPubMed Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science. 1999, 286: 2507-2510. 10.1126/science.286.5449.2507.CrossRefPubMed
Metadata
Title
Hormonal control of p53 and chemoprevention
Authors
D Joseph Jerry
Lisa M Minter
Klaus A Becker
Anneke C Blackburn
Publication date
01-06-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr431

Other articles of this Issue 3/2002

Breast Cancer Research 3/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine